2026 Biopharmaceutical Industry Research and Talent Insight Report Released

In the strategic inaugural year when China officially designated biopharmaceuticals as a "national emerging pillar industry," at the crossroads of global expansion and AI-driven transformation, CX Consulting's research team has officially released the "2026 Biopharmaceutical Industry Research and Talent Insight Report."

In the first half of 2026, China's biopharmaceutical industry faced a structural transformation under the dual pressures of slowing macroeconomic growth (GDP growth of 4.7%) and negative population growth (-2.41‰).

On the policy front, the 15th Five-Year Plan has for the first time designated biopharmaceuticals as a national emerging pillar industry, with a 50 billion yuan special fund being implemented. A series of supportive measures have been introduced including innovative drug price protection, expansion of the essential medicine list, and a dual "medical insurance + commercial insurance" coordination mechanism. The industry is undergoing a comprehensive shift from "scale expansion" to "quality and efficiency growth."

On the industry front, primary market financing surged 87.7% year-on-year, but the secondary market faced pressure and divergence. Capital became highly concentrated in hard-core technology sectors including AI pharmaceuticals, cell therapy, and radiopharmaceuticals. Global transaction volume reached $170.8 billion, with China accounting for over 60%. The outbound licensing model is evolving from License-out to deeper value-sharing Co-Co partnerships.

On the R&D front, 38 innovative drugs were approved in China, with domestic products accounting for over 80%. Eleven new target drugs were all domestically developed, with China achieving global leadership in solid tumor CAR-T and bispecific antibody ADC therapies.

On the talent front, the industry entered a phase of "precision replacement." AI skills anxiety emerged as the primary career crisis, with over 70% of professionals actively pursuing self-learning, though corporate training systems lag behind. There is a notable shortage of internationally experienced interdisciplinary talent, with job-hopping premiums reaching 30-60%. The era of universal salary increases has ended, with only 22.2% of employees receiving salary adjustments, though core R&D positions continue to command significant premiums.

Overall, the industry is experiencing a critical period of both pain and renewal. AI transformation, accelerated globalization, and value divergence are the dominant themes. Companies and talent with technological expertise and global capabilities will gain a competitive advantage in the new cycle.

The report is based on 3,240 talent questionnaires, corporate interviews, and data modeling, providing the most practical and decision-relevant insights for enterprise recruitment, talent job seeking, and career planning.

Key areas covered in the 89-page report include:
- Macro policy cycles and industry growth drivers
- Biopharmaceutical capital markets, transactions, and M&A landscape
- Deep insights into 7 key sectors: ADC, TCE, CGT, GLP-1, AI Pharmaceuticals, Small Nucleic Acids, and Traditional Chinese Medicine
- Organizational capability evolution and talent market restructuring
- Critical talent gaps and median salary benchmarks
- Industry risk indicators and future outlook

Based on survey data, 22.2% of employees received salary adjustments in the first half of 2026, with the average job-hopping salary increase at 16.4%. Early-stage R&D and project management positions saw the highest increases. The industry's key talent gaps include AI-fluent researchers, cross-border business development professionals, clinical operation leaders, and CMC experts.

Looking ahead to the second half of 2026, the industry expects continued momentum in AI-pharma integration, accelerated global expansion, and increased focus on differentiated innovation. The report identifies five core areas of focus for innovative drug R&D, as well as key industry challenges including regulatory complexity, global competition, and talent retention.